Healthcare utilization and cost of pneumococcal disease in the United States
SS Huang, KM Johnson, GT Ray, P Wroe, TA Lieu… - Vaccine, 2011 - Elsevier
BACKGROUND: Streptococcus pneumoniae continues to cause a variety of common clinical
syndromes, despite vaccination programs for both adults and children. The total US burden …
syndromes, despite vaccination programs for both adults and children. The total US burden …
Choosing between 7-, 10-and 13-valent pneumococcal conjugate vaccines in childhood: a review of economic evaluations (2006–2014)
DBC Wu, N Chaiyakunapruk, HY Chong, P Beutels - Vaccine, 2015 - Elsevier
Background Seven-valent pneumococcal conjugate vaccines (PCV7) have been used in
children for more than a decade. Given the observed increase in disease caused by …
children for more than a decade. Given the observed increase in disease caused by …
Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions
I Ogilvie, A El Khoury, Y Cui, E Dasbach… - Vaccine, 2009 - Elsevier
Streptococcus pneumoniae infections in adults are associated with substantial morbidity,
mortality, and costs. A literature review was conducted to identify strengths and limitations of …
mortality, and costs. A literature review was conducted to identify strengths and limitations of …
Do aluminum vaccine adjuvants contribute to the rising prevalence of autism?
L Tomljenovic, CA Shaw - Journal of inorganic biochemistry, 2011 - Elsevier
Autism spectrum disorders (ASD) are serious multisystem developmental disorders and an
urgent global public health concern. Dysfunctional immunity and impaired brain function are …
urgent global public health concern. Dysfunctional immunity and impaired brain function are …
Experimental human pneumococcal carriage
JF Gritzfeld, AD Wright, AM Collins… - JoVE (Journal of …, 2013 - jove.com
Experimental human pneumococcal carriage (EHPC) is scientifically important because
nasopharyngeal carriage of Streptococcus pneumoniae is both the major source of …
nasopharyngeal carriage of Streptococcus pneumoniae is both the major source of …
[HTML][HTML] Determinants of parental vaccine hesitancy in Canada: results from the 2017 Childhood National Immunization Coverage Survey
R Chen, M Guay, NL Gilbert, E Dubé, HO Witteman… - BMC Public Health, 2023 - Springer
Abstract Background In 2019, the World Health Organization (WHO) designated vaccine
hesitancy as one of the ten leading threats to global health. Vaccine hesitancy exists when …
hesitancy as one of the ten leading threats to global health. Vaccine hesitancy exists when …
[HTML][HTML] Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A …
JJ LeBlanc, M ElSherif, L Ye, D MacKinnon-Cameron… - Vaccine, 2019 - Elsevier
Background The 13-valent pneumococcal conjugate vaccine (PCV13) was recently shown
to be effective against PCV13-type invasive pneumococcal disease (IPD) and …
to be effective against PCV13-type invasive pneumococcal disease (IPD) and …
[HTML][HTML] Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada
M Wilson, M Wasserman, T Jadavi, M Postma… - Infectious diseases and …, 2018 - Springer
Abstract Introduction Pneumococcal conjugate vaccines (PCVs) have been available in
Canada since 2001, with 13-valent PCV (PCV13) added to the infant routine immunization …
Canada since 2001, with 13-valent PCV (PCV13) added to the infant routine immunization …
Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model
E Delgleize, O Leeuwenkamp, E Theodorou… - BMJ open, 2016 - bmjopen.bmj.com
Objectives In 2010, the 13-valent pneumococcal conjugate vaccine (PCV-13) replaced the 7-
valent vaccine (introduced in 2006) for vaccination against invasive pneumococcal diseases …
valent vaccine (introduced in 2006) for vaccination against invasive pneumococcal diseases …
[HTML][HTML] Cost-effectiveness of 2+ 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
SR Earnshaw, CL McDade, G Zanotti… - BMC infectious …, 2012 - Springer
Background Thirteen-valent pneumococcal conjugate vaccine (PCV13) and 10-valent
pneumococcal conjugate vaccine (PCV10) are two recently approved vaccines for the active …
pneumococcal conjugate vaccine (PCV10) are two recently approved vaccines for the active …